Equities

Spruce Biosciences Inc

SPRB:NAQ

Spruce Biosciences Inc

Actions
  • Price (USD)0.5112
  • Today's Change-0.015 / -2.78%
  • Shares traded203.33k
  • 1 Year change-52.67%
  • Beta2.3411
Data delayed at least 15 minutes, as of Nov 13 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders with significant unmet medical needs. The Company is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). It is also developing Tildacerfont for females suffering from polycystic ovary syndrome (PCOS). It has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with elevated levels of androstenedione (A4) at baseline. It has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 at baseline focused on glucocorticoid reduction. The Company also investigates tildacerfont for the treatment of classic CAH in children.

  • Revenue in USD (TTM)7.10m
  • Net income in USD-39.43m
  • Incorporated2014
  • Employees22.00
  • Location
    Spruce Biosciences Inc611 Gateway Boulevard, Suite 740SOUTH SAN FRANCISCO 94080United StatesUSA
  • Phone+1 (415) 655-4168
  • Fax+1 (302) 636-5454
  • Websitehttps://sprucebio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Promis Neurosciences Inc0.00-12.20m19.73m6.00---------0.6924-0.69240.00-0.12010.00----0.00-839.15-144.28---262.23-------2,271,047.00------------26.85------
Kazia Therapeutics Ltd (ADR)14.74k-13.37m19.77m12.00--1.85--1,341.55-8.11-8.110.0083.450.0007--73.97---63.98-46.35-82.39-54.75-----90,714.45-497.17----0.1297--979.43-28.3118.19------
Goldenwell Biotech Inc940.00-137.11k19.80m----5,169.71--21,063.83-0.0014-0.00140.000010.000040.00480.0031-----69.82---70.29--42.55---14,586.17--21.43--0.00---95.10--88.13------
MEI Pharma Inc65.30m17.78m20.92m28.001.180.63361.150.32042.672.679.804.960.8052--1,536.402,332,036.0021.92-21.0926.64-23.99----27.23-72.23----0.00--33.7667.75155.84---49.68--
Pieris Pharmaceuticals Inc20.87m-23.82m21.35m46.00--1.14--1.02-19.12-19.1216.6714.170.3707--17.13453,739.10-42.31-28.41-66.27-39.69-----114.11-94.61----0.00--65.288.0326.25---36.82--
Spruce Biosciences Inc7.10m-39.43m21.72m22.00--0.4206--3.06-0.9598-0.95980.17281.250.0798----244,862.10-44.28-41.24-55.51-46.49-----555.23-1,774.39---121.120.0399-------3.77------
HST Global Inc0.00-123.45k22.03m1.00---------0.0209-0.02090.00-0.00040.00-------3,300.80-5,836.01---------------27.315.81-------0.7858------
Neurobo Pharmaceuticals Inc0.00-27.73m22.06m8.00--1.70-----4.77-4.770.001.500.00----0.00-114.20-95.57-159.68-135.64------------0.00------10.72--75.54--
Unity Biotechnology Inc0.00-19.05m22.24m19.00--1.57-----1.14-1.140.000.83940.00----0.00-32.73-47.21-38.49-53.51-------6,395.92----0.00---100.00--10.36---61.28--
Bullfrog AI Holdings, Inc.65.00k-6.08m22.57m4.00--3.78--347.19-0.8441-0.84410.0090.68600.0107----16,250.00-100.10---117.94--92.00---9,331.34-----328.510.0596--550.00---91.11------
Ibio Inc225.00k-15.44m23.30m16.00--1.03--103.56-7.74-10.980.05862.470.0064--0.490714,062.50-44.16-27.69-69.38-33.13-----6,863.56-1,862.11----0.0689-----35.5247.31---26.66--
Palatin Technologies, Inc.4.49m-29.74m23.46m30.00------5.22-1.97-1.970.2981-0.00620.31310.37133.08149,669.70-207.35-55.28-1,527.99-69.0897.83---662.26-1,359.141.01-------7.49-40.52-23.71--3.31--
Mira Pharmaceuticals Inc0.00-12.78m23.65m3.00--10.66-----0.8562-0.85620.000.15010.00----0.00-373.77---737.47-------------3.170.00-------69.77------
Cognition Therapeutics Inc0.00-31.08m24.02m25.00--1.04-----0.9317-0.93170.000.57360.00----0.00-79.36---104.49-------------263.290.00-------20.52------
Lisata Therapeutics Inc0.00-21.07m24.21m25.00--0.6331-----2.56-2.560.004.600.00----0.00-40.16-45.97-43.61-50.47------------0.00------61.57------
Data as of Nov 13 2024. Currency figures normalised to Spruce Biosciences Inc's reporting currency: US Dollar USD

Institutional shareholders

18.14%Per cent of shares held by top holders
HolderShares% Held
Rock Springs Capital Management LPas of 30 Jun 20242.61m6.32%
Acadian Asset Management LLCas of 30 Jun 20241.37m3.31%
The Vanguard Group, Inc.as of 30 Jun 2024855.28k2.07%
Altium Capital Management LPas of 30 Jun 2024811.17k1.96%
Almitas Capital LLCas of 30 Jun 2024396.51k0.96%
ExodusPoint Capital Management LPas of 30 Jun 2024386.70k0.94%
Renaissance Technologies LLCas of 30 Jun 2024366.10k0.89%
Adar1 Capital Management LLCas of 30 Jun 2024355.22k0.86%
Geode Capital Management LLCas of 30 Jun 2024204.00k0.49%
683 Capital Management LLCas of 30 Jun 2024140.93k0.34%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.